AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...

Domestic pharma valuations are rich in the context of long-term risks, such as slower growth and regulatory interventions, ...

Indian pharmaceutical companies, which benefited from sector tailwinds such as stable generic pricing and shortage-led ...

A U.S. appeals court ruled that Novartis can't prevent MSN Pharmaceuticals' proposed generic of heart drug Entresto.

Leerink initiated coverage of ANI Pharmaceuticals (ANIP) with an Outperform rating and $80 price target The firm believes the market is yet to ...